Treatment of Relapsed/Refractory Non Hodgkin Lymphoma Patients with Venetoclax Therapy: A Single-Center Evaluation of off-label use
ConclusionVenetoclax therapy in a real-world cohort offered modest benefits in heavily-pretreated patients. Adverse events were observed at higher incidence compared to clinical trials. A wide heterogeneity of venetoclax dose escalation, multi-agent combinations, and timing of initiation were identified and would best be investigated in subsequent clinical trials.
Conditions: Lung Transplant Failure and Rejection; Primary Graft Dysfunction Intervention: Other: blood and exhaled breath specimens Sponsor: University Hospital, Antwerp Recruiting
Conditions: Chronic Pain; Liver Transplantation Intervention: Drug: FK506 Sponsors: The Second Hospital of Tangshan; Chinese PLA General Hospital Recruiting
Condition: Multiple Myeloma Interventions: Drug: CellProtect; Drug: Isatuximab Sponsors: Karolinska Institutet; Sanofi Not yet recruiting
Condition: Multiple Myeloma Intervention: Drug: autologous NK cells Sponsor: Karolinska University Hospital Active, not recruiting
Authors: Guillen-Climent S, García-Vázquez A, Martínez-Ciarpaglini C PMID: 32951879 [PubMed - as supplied by publisher]
CONCLUSION: sAPRIL, a simple, promising blood test, which can be measured by ELISA, will seemingly attain a place in the wide range of prognostic markers in CLL. Prospective large-scale studies are required to validate and confirm the feasibility of the proposed cut-off level of 2.04 ng/ml as a predictor of time to treatment in treatment naive CLL patients. PMID: 32950049 [PubMed - as supplied by publisher]
CONCLUSIONS: SRFA is an effective minimal-invasive treatment option in pediatric patients with liver tumors of different etiologies. PMID: 32954876 [PubMed - in process]
Conclusions: In BA infants, it is possible to determine CT-based body metrics during LT screening with very strong interobserver agreement. Poor correlation between CT-based body metrics and MUAC suggests that CT-based body metrics provide additional information on body composition in BA infants, such as relative muscle mass.
Conclusions: AT after KP confirmed conflicting results; therefore, multicentered, prospective, randomized control studies are needed to better understand its utility after KP, especially in the multidrug resistance spread era.
ConclusionVenetoclax therapy in a real-world cohort offered modest benefits in heavily pretreated patients. Adverse events were observed at a greater incidence than in the clinical trials. A wide heterogeneity of venetoclax dose escalation, multiagent combinations, and timing of initiation were identified and require investigation in subsequent clinical trials.